These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10891545)

  • 21. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma.
    Schramm A; Schulte JH; Astrahantseff K; Apostolov O; Limpt Vv; Sieverts H; Kuhfittig-Kulle S; Pfeiffer P; Versteeg R; Eggert A
    Cancer Lett; 2005 Oct; 228(1-2):143-53. PubMed ID: 15921851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas.
    Brinkschmidt C; Poremba C; Christiansen H; Simon R; Schäfer KL; Terpe HJ; Lampert F; Boecker W; Dockhorn-Dworniczak B
    Br J Cancer; 1998 Jun; 77(12):2223-9. PubMed ID: 9649137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis.
    Rydén M; Sehgal R; Dominici C; Schilling FH; Ibáñez CF; Kogner P
    Br J Cancer; 1996 Sep; 74(5):773-9. PubMed ID: 8795581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
    Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
    J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The MYCN enigma: significance of MYCN expression in neuroblastoma.
    Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
    Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
    Haber M; Smith J; Bordow SB; Flemming C; Cohn SL; London WB; Marshall GM; Norris MD
    J Clin Oncol; 2006 Apr; 24(10):1546-53. PubMed ID: 16575006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibody to human Trk-A: diagnostic and therapeutic potential in neuroblastoma.
    Kramer K; Gerald W; LeSauteur L; Saragovi HU; Cheung NK
    Eur J Cancer; 1997 Oct; 33(12):2090-1. PubMed ID: 9516859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis.
    Kogner P; Barbany G; Dominici C; Castello MA; Raschellá G; Persson H
    Cancer Res; 1993 May; 53(9):2044-50. PubMed ID: 8481906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma.
    Choi LM; Kim NW; Zuo JJ; Gerbing R; Stram D; Lukens JN; Matthay KK; Seeger RC; Reynolds CP
    Med Pediatr Oncol; 2000 Dec; 35(6):647-50. PubMed ID: 11107138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reevaluation of trkA expression as a biological marker of neuroblastoma by high-sensitivity expression analysis--a study of 106 primary neuroblastomas treated in a single institute.
    Hishiki T; Saito T; Terui K; Sato Y; Takenouchi A; Yahata E; Ono S; Nakagawara A; Kamijo T; Nakamura Y; Matsunaga T; Yoshida H
    J Pediatr Surg; 2010 Dec; 45(12):2293-8. PubMed ID: 21129533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas.
    Schulte JH; Schramm A; Klein-Hitpass L; Klenk M; Wessels H; Hauffa BP; Eils J; Eils R; Brodeur GM; Schweigerer L; Havers W; Eggert A
    Oncogene; 2005 Jan; 24(1):165-77. PubMed ID: 15637590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of biologic factors on the surgical decision in advanced neuroblastoma.
    Hsu WM; Jen YM; Lee H; Kuo ML; Tsao PN; Chen CN; Lai DM; Lin MT; Lai HS; Chen WJ; Hsieh FJ
    Ann Surg Oncol; 2006 Feb; 13(2):238-44. PubMed ID: 16418884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of the TrkA or TrkB receptor tyrosine kinase alters the double-strand break (DSB) repair capacity of SY5Y neuroblastoma cells.
    Schulte JH; Kuhfittig-Kulle S; Klein-Hitpass L; Schramm A; Biard DS; Pfeiffer P; Eggert A
    DNA Repair (Amst); 2008 Oct; 7(10):1757-64. PubMed ID: 18678285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shc family expression in neuroblastoma: high expression of shcC is associated with a poor prognosis in advanced neuroblastoma.
    Terui E; Matsunaga T; Yoshida H; Kouchi K; Kuroda H; Hishiki T; Saito T; Yamada S; Shirasawa H; Ohnuma N
    Clin Cancer Res; 2005 May; 11(9):3280-7. PubMed ID: 15867224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High expression of the novel endothelin-converting enzyme genes, Nbla03145/ECEL1alpha and beta, is associated with favorable prognosis in human neuroblastomas.
    Kawamoto T; Ohira M; Hamano S; Hori T; Nakagawara A
    Int J Oncol; 2003 Apr; 22(4):815-22. PubMed ID: 12632073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas.
    Suzuki T; Bogenmann E; Shimada H; Stram D; Seeger RC
    J Natl Cancer Inst; 1993 Mar; 85(5):377-84. PubMed ID: 8433391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas.
    Takahashi M; Ozaki T; Todo S; Nakagawara A
    Oncol Rep; 2004 Oct; 12(4):811-6. PubMed ID: 15375504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in early and late responses between neurotrophin-stimulated trkA- and trkC-transfected SH-SY5Y neuroblastoma cells.
    Edsjö A; Hallberg B; Fagerström S; Larsson C; Axelson H; Påhlman S
    Cell Growth Differ; 2001 Jan; 12(1):39-50. PubMed ID: 11205744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.
    Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T
    Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles.
    Schulte JH; Schowe B; Mestdagh P; Kaderali L; Kalaghatgi P; Schlierf S; Vermeulen J; Brockmeyer B; Pajtler K; Thor T; de Preter K; Speleman F; Morik K; Eggert A; Vandesompele J; Schramm A
    Int J Cancer; 2010 Nov; 127(10):2374-85. PubMed ID: 20473924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.